TY  -  
T1  - High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma 
SN  -  /  
UR  - http://hdl.handle.net/10138/343682 
T3  -  
A1  - Kohtamäki, Laura; Arjama, Mariliina; Mäkelä, Siru; Ianevski, Philipp; Välimäki, Katja; Juteau, Susanna; Ilmonen, Suvi; Ungureanu, Daniela; Kallioniemi, Olli; Murumägi, Astrid; Hernberg, Micaela 
A2  -  
PB  -  
Y1  - 2022 
LA  - eng 
AB  - Therapy options for patients with metastatic melanoma (MM) have considerably improved over the past decade. However, many patients still need effective therapy after unsuccessful immunotherapy, especially patients with BRAF-negative tumors who lack the option of targeted treatment second line. Therefore, the elucidation of efficient and personalized therapy options for these patients is required. In this study, three patient-derived cancer cells (PDCs) were established from NRAS Q61-positive MM ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Malignant melanoma; Drug testing; Kinase inhibitors; Targeted therapy; NRAS; Personalized therapy; PI3K INHIBITOR GDC-0941; MUTANT MELANOMA; MEK INHIBITION; COMBINED BRAF; DOUBLE-BLIND; SENSITIVITY; MUTATIONS; KIT; MULTICENTER; DABRAFENIB; 3122 Cancers 
N1  -   
PP  -  
ER  -